Bikini moguls Natasha Oakley and Devin Brugman made the most of the Caribbean sun this week. The Monday Swimwear founders were spotted catching some rays and showing off their beach-ready bodies ...

This story first appeared in Adam’s Biotech Scorecard, a subscriber-only newsletter. STAT+ subscribers can sign up here to get it delivered to their inbox. The newsletter was supposed to be on ...

Sutro Biopharma is cutting 65 jobs across two Bay Area locations. The layoffs, which are permanent according to state filings, will see three people lose their jobs at Sutro’s South San ...

For more, head to our Jeans Month hub. For a while now, there’s been a noticeable gap in my closet: a pair of gray jeans. Gray denim has long suffered from a bit of an image problem ...

H.C. Wainwright downgraded Sutro Biopharma (STRO) to Neutral from Buy with a price target of $2, down from $12, after the company announced a strategic realignment focused on advancing its next ...

The late-breaking oral presentation at SGO 2025 highlights consistent response rates observed in patients across all levels of FRα expression of 25% or greater – SOUTH SAN FRANCISCO, CA, USA I March ...

The Texas Rangers will begin the season without starting pitcher Jon Gray after he sustained a fractured right wrist during his appearance on Friday. Gray, who was struck on his pitching wrist by ...

Limited-time offer. The Bunker was in the action inside the opening ten minutes when the Bunnies were attacking the line as Jye Gray looked to feed a ball through behind the Dragons defenders.

Sutro Biopharma Inc. has announced plans to prioritize its three wholly owned preclinical programs in its next-generation antibody-drug conjugate (ADC) pipeline, while deprioritizing additional ...

On Friday, Oppenheimer analysts downgraded Sutro Biopharma (NASDAQ:STRO) stock from Outperform to Perform, following the company’s announcement of its fourth-quarter 2024 financial results and ...

Sutro Biopharma (NASDAQ:STRO) fell ~14% in the premarket on Friday after the company announced its decision to deprioritize its studies into the antibody-drug conjugate luveltamab tazevibulin as ...

Sutro Bio­phar­ma is re­duc­ing its head­count by 50%, ap­point­ing a new CEO, shut­ting down its on­ly fac­to­ry, and shift­ing away from its lead can­di­date. … ...